Extra chemotherapy around surgery for high-risk soft-tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether giving stronger chemotherapy before and/or after surgery helps people with high-risk, resectable soft-tissue sarcoma. It aims to lower the chance the cancer comes back by improving treatment around the time of the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed soft-tissue sarcoma diagnosis from a recognized French pathology network
- Your tumor is a grade 2 or 3 (how aggressive it looks under the microscope)
- Your cancer has not spread to distant organs and can be fully removed by surgery
- You have not had prior treatment for this sarcoma before starting the study
- You must be an adult (18+) with a life expectancy of at least 3 months and be well enough to do daily activities (ECOG 0–1)
- You need a measurable tumor spot on scan (meeting specific size rules), and you must be able to provide an archived tumor sample
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at stored tumor tissue (or takes a new biopsy) to measure specific tumor markers. Researchers want to see whether these markers match how well chemotherapy works before surgery for soft-tissue sarcoma.
This trial compares two chemotherapy medicines—oral cyclophosphamide versus doxorubicin—in people age 65 and older with advanced soft-tissue sarcoma that can’t be cured with surgery or radiation. It aims to see which treatment works better and is more tolerable for this age group.
This Phase 3 trial tests whether giving chemotherapy around the time of surgery (before/after) can improve outcomes for people with high-risk localized soft-tissue sarcoma. It uses special tumor testing (CINSARC) to help identify higher-risk patients who may benefit.
This trial tests a step-by-step (sequential) chemotherapy plan given before surgery for adults with specific types of soft tissue sarcoma. The goal is to shrink or control the tumor before the operation and see how well this approach works and is tolerated.
This trial tests combining anlotinib (a targeted therapy), doxorubicin (chemotherapy), and radiation given before surgery to shrink high-grade soft tissue sarcomas. The goal is to make the tumor easier to remove and improve outcomes.
This trial tests a new approach for high-risk soft tissue sarcoma of the arm, leg, or trunk. Before surgery, you would receive chemotherapy combined with local hyperthermia (a treatment that gently heats the tumor area) to see if this can improve outcomes.
Hear when a new Non-metastatic Soft-tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.